Certara, Inc. (CERT)
Health Care · Drug development software and consulting / computational pharmacology · NASDAQ
Certara utilizes proprietary biosimulation software and expert-led AI to help pharmaceutical companies optimize drug development and increase the probability of regulatory approval.
What Certara, Inc. does
Certara is a global leader in biosimulation science, technology, and consulting services for Model-Informed Drug Development (MIDD), which uses mathematical models derived from preclinical, clinical, and evidence data to optimize decision-making in pharmaceutical research, development, and commercialization. The company provides proprietary biosimulation platforms, curated datasets, regulatory consulting, and AI-enhanced software solutions designed to reduce drug development costs, accelerate timelines, and increase the probability of regulatory approval. Certara's customers have received over 90% of all novel FDA drug approvals from 2014-2025, and the company serves more than 2,600 life sciences companies and academic institutions across therapeutic areas ranging from cancer to rare diseases.
Themes: drug development productivity / R&D optimization, AI-enhanced scientific computing, regulatory science / compliance automation, computational pharmacology / biosimulation, clinical trial design and optimization, data analytics for life sciences
Fundamentals
- Price$8.43 as of 2026-08-21 close
- Market cap$1.3B as of 2026-08-21
- 1-year return-21.7% 2025-08-21 close $10.77 → 2026-08-21 close $8.43
- P/En/a negative earnings
- Net margin-16.8% as of 2026-08-24
- Gross margin+61.9% as of 2026-08-24
- ROE-6.7% as of 2026-08-24
- Debt / equity0.30 as of 2026-08-24
- Revenue growth (YoY)+0.7% as of 2026-08-24
- Revenue CAGR (3y)+7.7% SEC XBRL
- Beta1.45 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How CERT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Certara, Inc. looks technically
Certara, Inc. (CERT) is trading 14.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 190 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day high about 2 trading days ago. It is 39.3% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 14.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.07 | $7.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.37 | $7.37 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 190 trading days ago — a "death cross", a bearish long-term signal | 190 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 14.3% above | +14.3% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 16.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($6.33 to $8.88) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 82.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.88 | $13.88 |
|---|---|---|
| From the 52-week high | it is 39.3% below its 52-week high (its highest price of the past year) | -39.3% |
| Above the 52-week low | it is 89.4% above its 52-week low (its lowest price of the past year) | +89.4% |
| Below the 52-week high | it is 39.3% below its highest point of the past year | 39.3% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $45.47 (set on 2021-11-04) | $45.47 |
| Given back of the 52-week move | over the past year its closes ranged ($4.48 to $13.60), and it has recovered roughly a third of its fall from last year’s high — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.12 to $10.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.3% |
| From the all-time high | it is 81.5% below its all-time high | -81.5% |
| Nearest price level | it is sitting right on a support level at $8.40 — a price it turned at twice since 2025-12-15, most recently on 2026-08-03. Since 2024-08-21 it has 4 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $4.45 (set on 2026-05-15) | $4.45 |
| Above the all-time low | it is 89.4% above its all-time low | +89.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3798 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3798 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.65 and $8.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.65 – $8.09 – $8.54 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges above its 200-day average price (14.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.8% since the prior reading | +1.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Gap filled | a 22.6% gap down opened on 2026-08-04 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 20.7 percentage points (the stock gained 23.1% while the market gained 2.3%) | +20.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 60.0 percentage points (the stock gained 63.1% while the market gained 3.1%) | +60.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.4 percentage points (the stock gained 30.5% while the market gained 11.1%) | +19.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 42.2 percentage points (the stock lost 21.7% while the market gained 20.5%) | -42.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 29% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.5% of the share price. | +28.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.63 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +27.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $8.08 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +4.3% |
Price levels it has turned at before
CERT last closed at $8.43 on 2026-08-21. Since 2024-08-21 it has turned at 4 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.40 | Support | 0.3% below the last close | turned there twice · 2025-12-15 to 2026-08-03 |
| $8.64 | Resistance | 2.5% above the last close | turned there twice · 2025-04-09 to 2026-01-02 |
| $9.36 | Resistance | 11.0% above the last close | turned there three times · 2024-11-21 to 2025-12-22 |
| $7.39 | Support | 12.3% below the last close | turned there twice · 2026-07-07 to 2026-07-16 |
| $10.00 | Resistance | 18.6% above the last close | turned there four times · 2024-10-24 to 2026-01-08 |
| $6.46 | Support | 23.4% below the last close | turned there three times · 2026-04-22 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.33 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$8.19 range $7.00 – $9.00; median $8.20
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CERT
- Consensus EPS estimate$0.08856 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on pharmaceutical and biotech industry R&D spending, which is subject to economic cycles, regulatory changes, and strategic shifts in drug development strategy","Regulatory risk: AI and ML technologies embedded in models and documents must meet FDA transparency, reproducibility, and explainability standards, and any regulatory clarifications could impact product viability or require costly redesign","Competition from other MIDD service providers, in-house modeling capabilities developed by large pharma, and potential disruption from alternative drug development methodologies or emerging competitors with AI-native platforms"]
What changed in the latest 10-Q
AI-assisted comparison of CERT's 10-Q filed 2026-05-11 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added description of company as 'global leader in biosimulation science, technology and consulting services' (newer 2026-05-11 filing)
- Added statement that MIDD 'utilizes biological and statistical models derived from preclinical, clinical, and evidence data' (newer 2026-05-11)
- Added definition that 'Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation' (newer 2026-05-11)
- Changed pharmaceutical industry R&D spending from '$270 billion annually' to 'more than $290 billion annually' (newer 2026-05-11)
- Added new paragraph on AI approach: 'Our approach to AI is grounded in our long-standing expertise in mechanistic and empirical modeling' with discussion of expert-in-the-loop model (newer 2026-05-11)
- Added phrase 'scientifically based solutions' before data solutions description (newer 2026-05-11)
- Added reference to 'generative AI applications' specifically in addition to 'AI application' (newer 2026-05-11)
- Added new paragraph: 'We apply AI capabilities within established modeling environments and under the supervision of experienced scientists and regulatory experts' (newer 2026-05-11)
- Added references to specific regulatory agencies: UK's MHRA, China's NMPA (newer 2026-05-11)
- Updated customer count from 'more than 2,400' to 'more than 2,600 life sciences companies' (newer 2026-05-11)
- Updated projects count from 'more than 9,000' to 'more than 10,000 customer projects' (newer 2026-05-11)
- Updated software user count from 'more than 94,000 users' to 'more than 160,000 users' (newer 2026-05-11)
- Changed regulatory agencies count from '23 global drug regulatory agencies' to '20 global drug regulatory agencies' (newer 2026-05-11)
- Removed:
- Removed 'biotech industry' from description; changed to 'biopharmaceutical and biotech industry' (older 2025-11-06 had 'biopharmaceutical industry' only)
- Removed 'Biosimulation and MIDD can increase the probability of success in bringing a new drug to market and decrease the costs of drug development' standalone sentence (older 2025-11-06)
- Removed 'In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug development process as new products must be both approved by regulators and adopted by the market' (older 2025-11-06)
- Removed 'and drug development experience' after 'scientific understanding'; replaced with 'drug research and development experience' (older 2025-11-06)
- Removed 'solutions' descriptor before 'for the collection, standardization, validation, storage, and analysis'; changed to 'scientifically based solutions' (newer added more specificity)
- Removed reference to 'evidence data' as separate item; consolidated in older version (older 2025-11-06)
- Removed 'and results' after 'data'; newer version adds 'references and results' (older 2025-11-06 had 'data and results')
- Removed 'an AI application' phrasing; replaced with 'generative AI applications' (newer 2026-05-11)
- Removed paragraph: 'We believe that AI predictive models will continue to enhance the accuracy and usefulness of biosimulation models and will be utilized broadly across drug development' (older 2025-11-06)
- Removed 'Our strategy is to create and apply validated software applications that can be used broadly in the life science industry. We offer services, leveraging our technology,' introductory framing (older 2025-11-06)
- Removed specific mention of 'Pharmaceuticals and Medical Devices Agency (the "PMDA")' in favor of 'Japan's PMDA' shorthand (newer 2026-05-11)
- Removed reference to '2024 Annual Report'; changed to '2025 Annual Report' (newer 2026-05-11)
- Reworded:
- Changed 'biosimulation technology and solutions' to 'biosimulation science, technology and consulting services' (newer 2026-05-11)
- Changed 'Our software and scientists' to 'Our technology and scientists' (newer 2026-05-11)
- Changed 'solutions for the collection' to 'scientifically based solutions for the collection' (newer 2026-05-11)
- Changed 'preclinical and clinical data' to 'preclinical, clinical and evidence data' (newer 2026-05-11)
- Changed 'data and results' to 'data, references and results' (newer 2026-05-11)
- Changed 'regulatory services' to 'regulatory scientific services' (newer 2026-05-11)
- Changed 'Native AI and machine learning' to 'Native AI and machine learning' with expanded context about deployment (newer 2026-05-11)
- Changed 'to aid our clients' to 'to aid our customers' (newer 2026-05-11)
- Reordered reference list: older had 'FDA and Japan's PMDA'; newer lists 'FDA, UK's MHRA, Japan's PMDA, and China's NMPA' (newer 2026-05-11)
- Notes:
- Text is truncated at 'Bookings vary from period to period depending on' in both versions, limiting full comparison of that section
- Older filing section appears to continue with data table showing 2024-2025 quarterly metrics; newer filing text cuts off before that table is shown
- Annual report reference changed from 2024 to 2025, consistent with progression of fiscal periods (Q3 2025 vs Q3 2024)
Risk Factors
- Added:
- Newer filing (2026-05-11) states Risk Factors reference '2025 Annual Report' rather than '2024 Annual Report'
- Newer filing (2026-05-11) reports share repurchase activity for three months ended March 31, 2026 with 5,814,484 shares repurchased at average price of $6.86 per share
- Newer filing (2026-05-11) reports remaining authorized repurchase amount of $17.4 million as of March 31, 2026
- Newer filing (2026-05-11) removes footnote (c) reference and associated disclosure about shares purchased from employees for tax payments on RSU vesting
- Newer filing (2026-05-11) removes entire 'Adoption of Executive Officer Severance Policy' subsection that appeared in older filing
- Removed:
- Older filing (2025-11-06) contained disclosure of Executive Officer Severance Policy adopted effective November 5, 2025, with details on severance benefits for executives and CEO
- Older filing (2025-11-06) included footnote (c) explaining that shares purchased included 5,266 shares tendered by employees for tax payments on RSU vesting in third quarter of 2025
- Older filing (2025-11-06) reported share repurchase activity for three months ended September 30, 2025 with 1,235,664 total shares and 1,230,398 shares repurchased as part of program
- Older filing (2025-11-06) reported remaining authorized repurchase amount of $61.3 million as of September 30, 2025
- Reworded:
- Risk Factors Item 1A reference changed from '2024 Annual Report' (2025-11-06 filing) to '2025 Annual Report' (2026-05-11 filing)
- Older filing (2025-11-06) contains typo 'condense consolidated statement' vs. newer filing (2026-05-11) states 'condensed consolidated statement' in footnote (b)
- Signatory changed from William F. Feehery, Chief Executive Officer (2025-11-06 filing) to Jon Resnick, Chief Executive Officer (2026-05-11 filing)
- Notes:
- The comparison reflects different quarterly periods (Q3 2025 vs. Q1 2026), which accounts for differences in share repurchase activity and remaining authorization amounts
- The Executive Officer Severance Policy disclosure removal is consistent with it being a one-time disclosure adopted in November 2025; its absence from subsequent quarterly filing may reflect normal disclosure practices rather than a policy change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CERT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CERT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 23,190,614
- Reported value $132,186,501
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CERT had 28,839,594 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CERT had 18.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.73 days to cover at the same settlement.
- Reported short interest (shares) 28,839,594
- Short interest (% of shares outstanding) 18.9%
- Prior settlement (shares) 29,729,468
- Reported change -2.99%
- Days to cover (reported) 7.73
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Simulations Plus (SLP)
- Charles River Laboratories (CRL)
- Parexel (now part of EAE)
- Covance (part of LabCorp Drug Development)
- IQVIA
- Exscientia
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CERT vs…
Frequently asked questions
What does Certara, Inc. (CERT) do?
Certara is a global leader in biosimulation science, technology, and consulting services for Model-Informed Drug Development (MIDD), which uses mathematical models derived from preclinical, clinical, and evidence data to optimize decision-making in pharmaceutical research, development, and commercialization.
What sector is Certara, Inc. (CERT) in?
Certara, Inc. (CERT) is classified in the Health Care sector. Its industry is Drug development software and consulting / computational pharmacology. It trades on NASDAQ.
Who are Certara, Inc.'s (CERT) competitors?
Notable peers of Certara, Inc. (CERT) include Simulations Plus, Charles River Laboratories, Parexel (now part of EAE), Covance (part of LabCorp Drug Development) and IQVIA. This peer set is informational only — not financial advice.
Is Certara, Inc. (CERT) overbought or oversold right now?
Certara, Inc. (CERT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CERT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.